Rozzi A - Search Results

1

Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.

Bossi P, Kornek G, Lanzetta G, Rozzi A, Füreder T, Locati L, Licitra L. Bossi P, et al. Among authors: rozzi a. Head Neck. 2013 Oct;35(10):1471-4. doi: 10.1002/hed.23170. Epub 2012 Oct 6. Head Neck. 2013. PMID: 23042567

2

Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study.

Rozzi A, Nardoni C, Corona M, Restuccia MR, Falbo T, Lanzetta G. Rozzi A, et al. J Chemother. 2010 Dec;22(6):419-23. doi: 10.1179/joc.2010.22.6.419. J Chemother. 2010. PMID: 21303751 Clinical Trial.

3

Editorial Comment to Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.

Rozzi A, Lanzetta G. Rozzi A, et al. Int J Urol. 2015 Oct;22(10):915. doi: 10.1111/iju.12870. Epub 2015 Jul 7. Int J Urol. 2015. PMID: 26153730 No abstract available.

4

Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.

Rozzi A, Salerno M, Bordin F, De Marco F, Di Nicola S, Lanzetta G. Rozzi A, et al. Med Oncol. 2011 Dec;28 Suppl 1:S426-32. doi: 10.1007/s12032-010-9749-z. Epub 2010 Nov 30. Med Oncol. 2011. PMID: 21116878 Clinical Trial.

5

Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.

Rozzi A, Santini D, Salerno M, Bordin F, Mancuso A, Minniti G, Nardoni C, Corona M, Falbo PT, Recine F, Lanzetta G. Rozzi A, et al. Med Oncol. 2013 Mar;30(1):407. doi: 10.1007/s12032-012-0407-5. Epub 2013 Jan 10. Med Oncol. 2013. PMID: 23307245 Clinical Trial.

6

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.

Rozzi A, Nardoni C, Corona M, Restuccia MR, Fabi A, Bria E, Minniti G, Lanzetta G. Rozzi A, et al. Support Care Cancer. 2011 May;19(5):697-701. doi: 10.1007/s00520-010-0893-y. Epub 2010 May 14. Support Care Cancer. 2011. PMID: 20467757 Clinical Trial.

7

Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.

Sonpavde G, Pond GR, Di Lorenzo G, Buonerba C, Rozzi A, Lanzetta G, Necchi A, Giannatempo P, Raggi D, Matsumoto K, Choueiri TK, Mullane S, Niegisch G, Albers P, Lee JL, Kitamura H, Kume H, Bellmunt J. Sonpavde G, et al. Among authors: rozzi a. Clin Genitourin Cancer. 2016 Dec;14(6):494-498. doi: 10.1016/j.clgc.2016.05.001. Epub 2016 May 12. Clin Genitourin Cancer. 2016. PMID: 27262369

8

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.

Buonerba C, Di Lorenzo G, Pond G, Cartenì G, Scagliarini S, Rozzi A, Quevedo FJ, Dorff T, Nappi L, Lanzetta G, Pagliaro L, Eigl BJ, Naik G, Ferro M, Galdiero M, De Placido S, Sonpavde G. Buonerba C, et al. Among authors: rozzi a. Front Pharmacol. 2016 Dec 20;7:487. doi: 10.3389/fphar.2016.00487. eCollection 2016. Front Pharmacol. 2016. PMID: 28066240 Free PMC article.

9

Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.

Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A. Lanzetta G, et al. Among authors: rozzi a. Anticancer Res. 2003 Nov-Dec;23(6D):5159-64. Anticancer Res. 2003. PMID: 14981983 Clinical Trial.

10

Developing drugs in cancer-related bone pain.

Lucchesi M, Lanzetta G, Antonuzzo A, Rozzi A, Sardi I, Favre C, Ripamonti CI, Santini D, Armento G. Lucchesi M, et al. Among authors: rozzi a. Crit Rev Oncol Hematol. 2017 Nov;119:66-74. doi: 10.1016/j.critrevonc.2017.08.005. Epub 2017 Aug 25. Crit Rev Oncol Hematol. 2017. PMID: 28893462 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page